The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: A systematic review and meta-analysis

British Journal of Clinical Pharmacology

Volumn 77, Issue 3, 2014, Pages 446-457

  Floyd, Christopher N ^a   Ferro, Albert ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

antiplatelet drugs; drug resistance; genetic

Indexed keywords

ANTIPLATELET DRUGS; DRUG RESISTANCE; GENETIC;

DRUG RESISTANCE; GENE FREQUENCY; GENOTYPE; HUMANS; INTEGRIN BETA3; ODDS RATIO; PHENOTYPE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84894425680     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12204     Document Type: Review

References (62)

1. Pinniger JL, Prunty FT,. Some observations on the blood-clotting mechanism; the role of fibrinogen and platelets, with reference to a case of congenital afibrinogenaemia. Br J Exp Pathol 1946; 27: 200-210.
2. Floyd C, Ferro A,. The platelet fibrinogen receptor: from megakaryocyte to the mortuary. J R Soc Med Cardiovasc Dis 2012; 1: 7.
3. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE,. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88: 907-914.
4. Newman PJ, Valentin N,. Human platelet alloantigens: recent findings, new perspectives. Thromb Haemost 1995; 74: 234-239.
5. Simsek S, Faber NM, Bleeker PM, Vlekke AB, Huiskes E, Goldschmeding R, von dem Borne AE,. Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allele-specific restriction enzyme) analysis. Blood 1993; 81: 835-840.
6. Lim J, Lal S, Ng KC, Ng KS, Saha N, Heng CK,. Variation of the platelet glycoprotein IIIa PI(A1/A2) allele frequencies in the three ethnic groups of Singapore. Int J Cardiol 2003; 90: 269-273.
7. Newman PJ, Derbes RS, Aster RH,. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989; 83: 1778-1781.
8. Corral J, Gonzalez-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V,. HPA-1 genotype in arterial thrombosis-role of HPA-1b polymorphism in platelet function. Blood Coagul Fibrinolysis 1997; 8: 284-290.
9. Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, Murphy S, FitzGerald GA,. Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets. Blood 2001; 97: 3093-3099.
10. Vijayan KV, Huang TC, Liu Y, Bernardo A, Dong JF, Goldschmidt-Clermont PJ, Alevriadou BR, Bray PF,. Shear stress augments the enhanced adhesive phenotype of cells expressing the Pro33 isoform of integrin beta3. FEBS Lett 2003; 540: 41-46.
11. Vijayan KV, Liu Y, Sun W, Ito M, Bray PF,. The Pro33 isoform of integrin beta3 enhances outside-in signaling in human platelets by regulating the activation of serine/threonine phosphatases. J Biol Chem 2005; 280: 21756-21762.
12. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF,. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 2000; 101: 1013-1018.
13. Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ,. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-1094.
14. Zhu MM, Weedon J, Clark LT,. Meta-analysis of the association of platelet glycoprotein IIIa PlA1/A2 polymorphism with myocardial infarction. Am J Cardiol 2000; 86: 1000-1005, A8.
15. Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L,. Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost 2001; 85: 626-633.
16. Goodman T, Ferro A, Sharma P,. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008; 66: 222-232.
17. Mantel N, Haenszel W,. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
18. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
19. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR,. Introduction to Meta-Analysis. Chichester, West Sussex, UK: John Wiley & Sons, Ltd., 2009.
20. Deeks JJ,. Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: 157-162.
21. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
22. Abderrazek F, Chakroun T, Addad F, Dridi Z, Gerotziafas G, Gamra H, Hassine M, Elalamy I,. The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin. Thromb Res 2010; 125: e265-268.
23. Bernardo E, Angiolillo DJ, Ramirez C, Cavallari U, Trabetti E, Sabate M, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C, Fernandez-Ortiz A,. Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. Platelets 2006; 17: 586-590.
24. Fontana P, Nolli S, Reber G, De Moerloose P,. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 2006; 4: 813-819.
25. Godeneche G, Sorel N, Ragot S, Chomel JC, Neau JP, Macchi L,. Stroke and aspirin non-responder patients: relation with hypertension and platelet response to adenosine diphosphate. Platelets 2009; 20: 471-477.
26. Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V,. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36: 276-280.
27. Jefferson BK, Foster JH, McCarthy JJ, Ginsburg G, Parker A, Kottke-Marchant K, Topol EJ,. Aspirin resistance and a single gene. Am J Cardiol 2005; 95: 805-808.
28. Kranzhofer R, Ruef J,. Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism. Platelets 2006; 17: 163-169.
29. Kunicki TJ, Williams SA, Nugent DJ, Harrison P, Segal HC, Syed A, Rothwell PM,. Lack of association between aspirin responsiveness and seven candidate gene haplotypes in patients with symptomatic vascular disease. Thromb Haemost 2009; 101: 123-133.
30. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS,. Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 2007; 119: 355-360.
31. Lordkipanidze M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C,. Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb Res 2011; 128: 47-53.
32. Macchi L, Christiaens L, Brabant S, Sorel N, Ragot S, Allal J, Mauco G, Brizard A,. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003; 42: 1115-1119.
33. Pamukcu B, Oflaz H, Nisanci Y,. The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 2005; 149: 675-680.
34. Pamukcu B, Oflaz H, Onur I, Hancer V, Yavuz S, Nisanci Y,. Impact of genetic polymorphisms on platelet function and aspirin resistance. Blood Coagul Fibrinolysis 2010; 21: 53-56.
35. Papp E, Havasi V, Bene J, Komlosi K, Czopf L, Magyar E, Feher C, Feher G, Horvath B, Marton Z, Alexy T, Habon T, Szabo L, Toth K, Melegh B,. Glycoprotein IIIA (PlA) polymorphism aspirin resistance: Is there any correlation? Ann Pharmacother 2005; 39: 1013-1018.
36. Andrioli G, Minuz P, Solero P, Pincelli S, Ortolani R, Lussignoli S, Bellavite P,. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa). Br J Haematol 2000; 110: 911-918.
37. Boudoulas KD, Cooke GE, Roos CM, Bray PF, Goldschmidt-Clermont PJ,. The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med 2001; 125: 112-115.
38. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ,. PI (A2) polymorphism and efficacy of aspirin. Lancet 1998; 351: 1253.
39. Cooke GE, Liu-Stratton Y, Ferketich AK, Moeschberger ML, Frid DJ, Magorien RD, Bray PF, Binkley PF, Goldschmidt-Clermont PJ,. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 2006; 47: 541-546.
40. Dropinski J, Musial J, Sanak M, Wegrzyn W, Nizankowski R, Szczeklik A,. Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease. Thromb Res 2007; 119: 301-303.
41. Isordia-Salas I, Olalde-Roman MJ, Santiago-German D, De La Pena NC, Valencia-Sanchez JS,. The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population. Thromb Res 2012; 130: e67-e72.
42. Lepantalo A, Mikkelsson J, Resendiz JC, Viiri L, Backman JT, Kankuri E, Karhunen PJ, Lassila R,. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95: 253-259.
43. Lim E, Carballo S, Cornelissen J, Ali ZA, Grignani R, Bellm S, Large S,. Dose-related efficacy of aspirin after coronary surgery in patients with PlA2 polymorphism (NCT00262275). Ann Thorac Surg 2007; 83: 134-138.
44. Stepien E, Szuldrzynski K, Branicka A, Stankiewicz E, Pazdan A, Zielinski L, Bozek M, Tomala M, Guzik B, Godlewski J, Pawelec T, Zmudka K,. The thrombin generation is associated with the PIA1/A2 beta3, integrin polymorphism in aspirin-treated patients with coronary artery disease: a role of statins. Pol Arch Med Wewn 2007; 117: 33-40.
45. Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W, Dropinski J, Waclawczyk T, Ulczok R, Bochenek A,. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg 2005; 130: 791-796.
46. Szczeklik A, Undas A, Sanak M, Frolow M, Wegrzyn W,. Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000; 110: 965-967.
47. Undas A, Sanak M, Musial J, Szczeklik A,. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 1999; 353: 982-983.
48. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A,. Pl (A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 2666-2672.
49. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Sabate M, Fernandez C, Stranieri C, Trabetti E, Pignatti PF, Macaya C,. PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 2004; 15: 89-93.
50. Dropinski J, Musial J, Jakiela B, Wegrzyn W, Sanak M, Szczeklik A,. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin. Thromb Haemost 2005; 94: 1300-1305.
51. Papp E, Havasi V, Bene J, Komlosi K, Talian G, Feher G, Horvath B, Szapary L, Toth K, Melegh B,. Does glycoprotein IIIa gene (Pl(A)) polymorphism influence clopidogrel resistance?: a study in older patients. Drugs Aging 2007; 24: 345-350.
52. Motovska Z, Widimsky P, Kvasnicka J, Petr R, Bilkova D, Hajkova J, Marinov L, Simek S, Kala P,. High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IMA gene polymorphism: A genetic substudy of PRAGUE-8 trial. Blood Coagul Fibrinolysis 2009; 20: 257-262.
53. Storey RF, Melissa Thornton S, Lawrance R, Husted S, Wickens M, Emanuelsson H, Cannon CP, Heptinstall S, Armstrong M,. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3. Platelets 2009; 20: 341-348.
54. Aalto-Setala K, Karhunen PJ, Mikkelsson J, Niemela K,. The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anticoagulants used. J Thromb Thrombolysis 2005; 20: 57-63.
55. Sirotkina OV, Khaspekova SG, Zabotina AM, Shimanova YV, Mazurov AV,. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists. Platelets 2007; 18: 506-514.
56. Verdoia M, Pergolini P, Camaro C, Restifo M, Rolla R, Schaffer A, Di Giovine G, Marino P, Bellomo G, Suryapranata H, De Luca G,. PlA1/PlA2 polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Blood Coagul Fibrinolysis 2013; 24: 411-418.
57. Weber AA, Jacobs C, Meila D, Weber S, Zotz RB, Scharf RE, Kelm M, Strauer BE, Schror K,. No evidence for an influence of the human platelet antigen-1 polymorphism on the antiplatelet effects of glycoprotein IIb/IIIa inhibitors. Pharmacogenetics 2002; 12: 581-583.
58. Wheeler GL, Braden GA, Bray PF, Marciniak SJ, Mascelli MA, Sane DC,. Reduced inhibition by abciximab in platelets with the PlA2 polymorphism. Am Heart J 2002; 143: 76-82.
59. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG,. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007; 28: 1702-1708.
60. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ,. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
61. Wenaweser P, Dorffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, Haeberli A, Hess OM,. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005; 45: 1748-1752.
62. Frelinger AL III, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, Michelson AD,. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120: 2586-2596